Biosimilar medical products – licensing, pharmacovigilance and interchangeability

1. Dolinar RO, Reilly MS. The future of biological therapy: a pathway forward for biosimilars. GaBI Journal. 2013; 2(1): 36–40.10.5639/gabij.2013.0201.014Search in Google Scholar

2. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012; 11 (7): 527–540.10.1038/nrd3746371437022743980Search in Google Scholar

3. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood 2012; 120 (26): 5111–5117.10.1182/blood-2012-04-42574423093622Search in Google Scholar

4. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev. 2007; 28: 625–652.10.1210/er.2007-000217785428Search in Google Scholar

5. EMA/CHMP/437/04 Rev 1. Guideline on Similar Biological Medicinal Products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.Search in Google Scholar

6. FDA. Information for Consumers (Biosimilars). Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approval/Applications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm.Search in Google Scholar

7. WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available at: http://www.who.int/biologicals/areas/biological_therapeutics,Biotherapeuticsforweb_22april2010.pdf.Search in Google Scholar

8. Health Canada. Fact Sheet: Subsequent Entry Biologics in Canada. Available at: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/activit/fs-fi/fs-fi_seb-pbu_07–2006-eng.php.Search in Google Scholar

9. Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals (Basel). 2012; 5(4): 353–368.10.3390/ph5040353376364424281406Search in Google Scholar

10. EMA. Guideline on similar biological medicinal products. 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/scientific_guideline/2009/09/WC500003517.pdf.Search in Google Scholar

11. EMA. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies—Non-clinical and Clinical Issues. 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/scientific_guideline/2012/06/WC500128686.pdfSearch in Google Scholar

12. EMA. Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use. 2012 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/scientific_guideline/2012/06/WC500128688.pdfSearch in Google Scholar

13. EMA. Guideline on Good Pharmacovigilance Practices. 2013 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/04/WC500142282.pdfSearch in Google Scholar

14. Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products. European Commission. Available at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf.Search in Google Scholar

15. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011; 3: 209–217.10.4161/mabs.3.2.15005309262221441787Search in Google Scholar

16. EMA. Guideline on Similar Biological Medicinal Products. 2001. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC50017.pdfSearch in Google Scholar

17. Scott C. A decade of process development. BioProcess Int. 2012; 10: 72–78.Search in Google Scholar

18. World Health Organization Executive Summary. Proceedings of the 55^th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 16-18 October 2012. www.who.int/medicines/services/inn/55th_Executive_Summary.pdf.Search in Google Scholar

19. Silverman E. Biosimilars: what’s in a name? BMJ 2014; 348: g27210.1136/bmj.g27224443479Search in Google Scholar

20. Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG. Pharmacovigilance and biosimilars: considerations, needs, and challenges. Expert Opin Biol Ther 2013; 13: 1039–47.10.1517/14712598.2013.78356023527621Search in Google Scholar

21. The Pharmaceuticals and Medical Devices Agency, Japan. March 2009 Guideline for the Quality, Safety, and Effectiveness of Biosimilar Products. Tokyo: Pharmaceuticals and Medical Devices Agency.Search in Google Scholar

22. World Health Organization. Apr 2009. Guidelines on Evaluation of Similar Biotherapeutic Products. Geneva: World Health Organization Expert Committee on Biological Standardization.Search in Google Scholar

23. World Health Organization. Jan 2014. Regulatory Expectations and Risk Assessment for Biotherapeutic Products: Scientific Principles to Consider.Search in Google Scholar

24. European Generic Medicines Association. Biosimilars Handbook, 2nd ed. 2011, Brussels: European Generic Medicines Association.Search in Google Scholar

25. Dörner T, Strand V, Castañeda-Hernández G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 72: 322–328.10.1136/annrheumdis-2012-20271523253920Search in Google Scholar

26. EMA. Questions and Answers on Biosimilar Medicines, 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf.Search in Google Scholar

27. Rovira, J, Espin J, Garcia L, Olry de Labry A. The Impact of Biosimilars’ Entry in the EU Market. Andalusian School of Public Health. 2011. Available at: http://citeseerx.ist.psu.edu/viewdoc/download?doi510.1.1.357.2218&rep5rep1&type5.pdf.Search in Google Scholar

28. Jelkmann W. Biosimilar epoetins and other “follow-on” biologics: update on the European experiences. Am J Hematol. 2010; 85: 771–780.10.1002/ajh.2180520706990Search in Google Scholar

29. France to allow biosimilars substitution. 2014. Available at: http://www.gabionline.net/Policies-Legislation/France-to-allow-biosimilars-substitution/(highlight)/france%20substitution.Search in Google Scholar

30. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014; 124: 3191–3196.10.1182/blood-2014-06-58361725298038Search in Google Scholar